| Univariable analysis | Multivariable analysis |
---|
HR (95% CI) |
p-value | HR (95% CI) |
p-value |
---|
Cohort I |
OS | 2.05 (1.10–3.82) |
0.024
| 1.93 (1.03–3.62) |
0.039
a
|
BCSS | 2.34 (1.00–5.47) | 0.051 | | |
RFS | 1.88 (0.90–3.97) | 0.095 | | |
Cohort II |
OS | 1.91 (1.39–2.63) |
<0.001
| 1.61 (1.09–2.39) |
0.018
b
|
BCSS | 1.93 (1.38–2.69) |
<0.001
| 1.58 (1.05–2.38) |
0.027
b
|
RFS | 1.75 (1.27–2.40) |
0.001
| 1.67 (1.13–2.48) |
0.010
b
|
- Low ANLN NF(ref) vs high ANLN NF
-
HR hazard ratio, CI confidence interval, ref referent group, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
- Significant correlations (p < 0.05) are indicated by bold numbers
-
aMultivariable analysis included adjustment for age
-
bMultivariable analysis included adjustment for Ki-67, tumor size, ER, PR, HER2, nodal status and age